NASDAQ:LMDX LumiraDx (LMDX) Stock Forecast, Price & News $0.48 -0.02 (-3.25%) (As of 05/26/2023 08:47 PM ET) Add Compare Share Share Today's Range$0.45▼$0.5150-Day Range$0.47▼$0.8652-Week Range$0.45▼$4.50Volume150,200 shsAverage Volume172,979 shsMarket Capitalization$152.59 millionP/E RatioN/ADividend YieldN/APrice Target$2.14 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media LumiraDx MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside346.2% Upside$2.14 Price TargetShort InterestBearish12.57% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.51) to ($0.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.88 out of 5 starsMedical Sector746th out of 1,010 stocksPharmaceutical Preparations Industry374th out of 494 stocks 3.3 Analyst's Opinion Consensus RatingLumiraDx has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.14, LumiraDx has a forecasted upside of 346.2% from its current price of $0.48.Amount of Analyst CoverageLumiraDx has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.57% of the float of LumiraDx has been sold short.Short Interest Ratio / Days to CoverLumiraDx has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in LumiraDx has recently increased by 2.93%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldLumiraDx does not currently pay a dividend.Dividend GrowthLumiraDx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LMDX. Previous Next 2.0 News and Social Media Coverage News SentimentLumiraDx has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for LumiraDx this week, compared to 2 articles on an average week.Search Interest4 people have searched for LMDX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added LumiraDx to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, LumiraDx insiders have not sold or bought any company stock.Percentage Held by Insiders35.41% of the stock of LumiraDx is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for LumiraDx are expected to grow in the coming year, from ($0.51) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of LumiraDx is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LumiraDx is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About LumiraDx (NASDAQ:LMDX) StockLumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom.Read More Receive LMDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LumiraDx and its competitors with MarketBeat's FREE daily newsletter. Email Address LMDX Stock News HeadlinesMay 21, 2023 | americanbankingnews.comLumiraDx (NASDAQ:LMDX) Price Target Cut to $1.00May 20, 2023 | americanbankingnews.comLumiraDx (NASDAQ:LMDX) Rating Reiterated by 500.comMay 29, 2023 | Stocks To Trade (Ad)15 A.I. Trading Opportunities a DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 20, 2023 | americanbankingnews.comLADENBURG THALM/SH SH Lowers LumiraDx (NASDAQ:LMDX) Price Target to $2.70May 18, 2023 | msn.comLadenburg Thalmann Maintains LumiraDx (LMDX) Buy RecommendationMay 18, 2023 | msn.comGoldman Sachs Maintains LumiraDx (LMDX) Neutral RecommendationMay 17, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for LumiraDxMay 17, 2023 | msn.comRaymond James Maintains LumiraDx (LMDX) Outperform RecommendationMay 29, 2023 | Stocks To Trade (Ad)15 A.I. Trading Opportunities a DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 17, 2023 | americanbankingnews.comShort Interest in LumiraDx Limited (NASDAQ:LMDX) Decreases By 6.0%May 16, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: LumiraDx (LMDX) and Aerovate Therapeutics (AVTE)May 16, 2023 | msn.comLumiraDx: Q1 Earnings InsightsMay 16, 2023 | finance.yahoo.comLumiraDx Limited (LMDX) Reports Q1 Loss, Tops Revenue EstimatesMay 16, 2023 | finanznachrichten.deLumiraDx Inc: LumiraDx Reports First Quarter 2023 ResultsMay 16, 2023 | finance.yahoo.comLumiraDx Reports First Quarter 2023 ResultsMay 15, 2023 | msn.comEarnings Preview For LumiraDxMay 9, 2023 | finance.yahoo.comLumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 16May 3, 2023 | finance.yahoo.comWill LumiraDx Limited (LMDX) Report Negative Q1 Earnings? What You Should KnowMay 1, 2023 | americanbankingnews.comLumiraDx Limited (NASDAQ:LMDX) Short Interest UpdateApril 24, 2023 | finance.yahoo.comLumiraDx Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyApril 7, 2023 | finance.yahoo.comIncreasing losses over year doesn't faze LumiraDx (NASDAQ:LMDX) investors as stock spikes 30% this past weekApril 7, 2023 | americanbankingnews.comLumiraDx (NASDAQ:LMDX) Given New $1.50 Price Target at Raymond JamesApril 6, 2023 | finance.yahoo.comRevamping LumiraDx: New Strategic Focus And Cost-Saving Initiatives AnnouncedApril 6, 2023 | finance.yahoo.comLumiraDx Announces Strategic Refocus and Cost Restructuring ProgramApril 2, 2023 | americanbankingnews.comLumiraDx Limited (NASDAQ:LMDX) Short Interest Up 10.1% in MarchMarch 25, 2023 | americanbankingnews.comThe Goldman Sachs Group Cuts LumiraDx (NASDAQ:LMDX) Price Target to $0.85March 24, 2023 | finance.yahoo.comLumiraDx Limited (NASDAQ:LMDX) Q4 2022 Earnings Call TranscriptSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive LMDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LumiraDx and its competitors with MarketBeat's FREE daily newsletter. Email Address LMDX Company Calendar Last Earnings3/21/2023Today5/29/2023Next Earnings (Estimated)8/17/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LMDX CUSIPN/A CIK1685428 Webwww.lumiradx.com Phone354-640-0540FaxN/AEmployees1,210Year FoundedN/APrice Target and Rating Average Stock Price Forecast$2.14 High Stock Price Forecast$4.00 Low Stock Price Forecast$0.85 Forecasted Upside/Downside+346.2%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-447,790,000.00 Net Margins-291.10% Pretax Margin-288.53% Return on Equity-2,145.42% Return on Assets-88.51% Debt Debt-to-Equity Ratio20.12 Current Ratio2.54 Quick Ratio1.51 Sales & Book Value Annual Sales$254.48 million Price / Sales0.60 Cash FlowN/A Price / Cash FlowN/A Book Value($0.48) per share Price / Book-1.00Miscellaneous Outstanding Shares318,550,000Free Float205,749,000Market Cap$152.59 million OptionableNot Optionable Beta0.96 Key ExecutivesMr. Ron Zwanziger (Age 69)Co-Founder, Chairman & CEO Dr. David Scott Ph.D. (Age 66)Co-Founder, CTO & Director Dr. Jerome F. McAleer Ph.D. (Age 67)Co-Founder, Chief Scientist & Director Mr. Dorian LeBlanc CPA (Age 47)CFO & VP of Global Operations Ms. Veronique Ameye (Age 46)Exec. VP & Gen. Counsel Ms. Colleen McMillenVP of CommunicationsAndy WardNational Sales Director - UKMr. Peter Scheu (Age 58)Pres of North American Commercial Operations Mr. David Walton DMS (Age 69)Chief Commercial Officer Dr. Nigel Lindner (Age 66)Chief Innovation Officer More ExecutivesKey CompetitorsOptiNoseNASDAQ:OPTNHeron TherapeuticsNASDAQ:HRTXGracell BiotechnologiesNASDAQ:GRCLCorvus PharmaceuticalsNASDAQ:CRVSLarimar TherapeuticsNASDAQ:LRMRView All CompetitorsInstitutional OwnershipBalyasny Asset Management L.P.Sold 1,710,746 shares on 5/16/2023Ownership: 0.478%Sound View Wealth Advisors Group LLCBought 35,000 shares on 5/12/2023Ownership: 0.022%Beacon Investment Advisory Services Inc.Bought 57,613 shares on 5/4/2023Ownership: 0.172%View All Institutional Transactions LMDX Stock - Frequently Asked Questions Should I buy or sell LumiraDx stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LumiraDx in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LMDX shares. View LMDX analyst ratings or view top-rated stocks. What is LumiraDx's stock price forecast for 2023? 3 analysts have issued 1 year target prices for LumiraDx's shares. Their LMDX share price forecasts range from $0.85 to $4.00. On average, they predict the company's stock price to reach $2.14 in the next twelve months. This suggests a possible upside of 346.2% from the stock's current price. View analysts price targets for LMDX or view top-rated stocks among Wall Street analysts. How have LMDX shares performed in 2023? LumiraDx's stock was trading at $0.90 at the beginning of 2023. Since then, LMDX shares have decreased by 46.8% and is now trading at $0.4790. View the best growth stocks for 2023 here. When is LumiraDx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 17th 2023. View our LMDX earnings forecast. How were LumiraDx's earnings last quarter? LumiraDx Limited (NASDAQ:LMDX) announced its quarterly earnings results on Tuesday, March, 21st. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.13. The company earned $41.12 million during the quarter, compared to analyst estimates of $38.41 million. LumiraDx had a negative net margin of 291.10% and a negative trailing twelve-month return on equity of 2,145.42%. What is LumiraDx's stock symbol? LumiraDx trades on the NASDAQ under the ticker symbol "LMDX." Who are LumiraDx's major shareholders? LumiraDx's stock is owned by many different institutional and retail investors. Top institutional shareholders include Balyasny Asset Management L.P. (0.48%), Beacon Investment Advisory Services Inc. (0.17%) and Sound View Wealth Advisors Group LLC (0.02%). How do I buy shares of LumiraDx? Shares of LMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is LumiraDx's stock price today? One share of LMDX stock can currently be purchased for approximately $0.48. How much money does LumiraDx make? LumiraDx (NASDAQ:LMDX) has a market capitalization of $152.59 million and generates $254.48 million in revenue each year. The company earns $-447,790,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis. How many employees does LumiraDx have? The company employs 1,210 workers across the globe. How can I contact LumiraDx? LumiraDx's mailing address is 99 SUMMER STREET SUITE 200, BOSTON MA, 02110. The official website for the company is www.lumiradx.com. The company can be reached via phone at 354-640-0540 or via email at ir@lumiradx.com. This page (NASDAQ:LMDX) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LumiraDx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.